Gregal (Tiotropium Bromide)

Gregal is indicated for the long‑term management of certain chronic respiratory diseases.

• Chronic obstructive pulmonary disease (COPD) – helps reduce the frequency of exacerbations and improves overall lung function.
• Asthma – used as an add‑on therapy for patients whose symptoms are not fully controlled with inhaled corticosteroids.
• Maintenance treatment – provides once‑daily bronchodilation to improve breathing capacity and lessen shortness of breath.
• Adults with stable disease – suitable for patients who require a long‑acting anticholinergic agent.
• May be considered when inhaled therapy adherence is a concern – oral administration offers an alternative route.

The safety profile of Gregal includes both common and less frequent adverse reactions observed in clinical use.

Common

• Dry mouth
• Throat irritation
• Cough
• Upper respiratory tract infection

Serious

• Paradoxical bronchospasm
• Severe allergic reaction (e.g., angioedema, rash)
• Urinary retention in patients with prostate enlargement

Before prescribing Gregal, clinicians should evaluate patient history and consider specific safety considerations.

• Assess for known hypersensitivity to tiotropium bromide or other anticholinergic agents.
• Use caution in patients with narrow-angle glaucoma or severe urinary retention.
• Monitor renal function, as reduced clearance may increase systemic exposure.
• Avoid initiating therapy in individuals with acute bronchospasm; stabilize condition first.
• Educate patients on proper oral administration technique to minimize local irritation.
• Review pregnancy and lactation status, as safety data are limited.
• Consider age‑related dose adjustments for elderly patients with comorbidities.

Gregal may interact with other medicines, and certain combinations should be avoided or used with caution.

Avoid

• Other anticholinergic drugs (e.g., ipratropium) – additive antimuscarinic effects may increase risk of dry mouth and urinary retention.
• Strong CYP3A4 inhibitors – may raise systemic levels of tiotropium.

Use with caution

• Beta‑agonists – concurrent use may enhance bronchodilation but requires monitoring for tachycardia.
• Diuretics – potential for increased dehydration and electrolyte imbalance.
• Medications affecting renal excretion (e.g., cimetidine) – may alter tiotropium clearance.